| 1.64 0.07 (4.46%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.08 | 1-year : | 2.4 |
| Resists | First : | 1.78 | Second : | 2.05 |
| Pivot price | 1.57  |
|||
| Supports | First : | 1.34 | Second : | 1.11 |
| MAs | MA(5) : | 1.61  |
MA(20) : | 1.63 |
| MA(100) : | 1.91 |
MA(250) : | 1.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.9 |
D(3) : | 54.9 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 2.71 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMMX ] has closed below upper band by 33.2%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.68 |
| Low: | 1.59 - 1.6 | 1.6 - 1.61 |
| Close: | 1.63 - 1.64 | 1.64 - 1.65 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Thu, 27 Mar 2025
Immix Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView
Sat, 08 Mar 2025
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - simplywall.st
Tue, 10 Dec 2024
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 39.7 (%) |
| Held by Institutions | 12.1 (%) |
| Shares Short | 367 (K) |
| Shares Short P.Month | 389 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.2 % |
| Return on Equity (ttm) | -147.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -2.16 |
| PEG Ratio | 0 |
| Price to Book value | 3.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|